There is one clinical trial.
The Investigators propose to set up a preventive trial of infection in hospital workers at risk of coronavirus infection by comparing the rate of SARS-Cov-2 infection in a population of negative SARS-Cov-2 hospital workers receiving preventively azithromycin, hydroxychloroquine or a Placebo
Description: The number of hospital workers with a positive serology or a positive PCR within 40 days of follow-up.Measure: To assess the impact of hydroxychloroquine and azithromycin on the prevention of SARS-CoV-2 contamination in hospital workers exposed to 40 days of treatment. Time: 3 months
Description: Clinical signs suggesting SARS-2 CoV infection confirmed by positive endonasal PCRMeasure: Reducing clinical episodes due to suspected SARS-2 CoV infection confirmed by PCR Time: 40 days
Description: number of seroconversion by serology between Day 0 and Day 40.Measure: Reducing seroconversion for SARS-CoV-2 without any clinical sign Time: 3 months
Description: number of cardiological severe adverse events assessed (ECG abnormalities : widening QT, ventricular arythmia, and cardiac arrests), other serious adverse events including hospitalizations, and deathsMeasure: Evaluation of drug tolerance in the study Time: 40 days
Description: Number of work stoppages over the periodMeasure: Evaluation on work stopping of hospital workers Time: 40 days
Description: Plasmatic concentrations of treatmentsMeasure: Observance of treatment measured by plasmatic concentrations of hydroxychloroquine or azythromycine Time: 40 days
Description: number of cardiac events, especialy ECG abnormalities (widening QT) due to treatmentsMeasure: Incidence of cardiologic events Time: 40 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports